| 1 |
32005219 | Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. | 2020 Jan 31 |
1 |
| 2 |
32341751 | Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation. | 2020 Apr 14 |
5 |
| 3 |
33070705 | Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. | 2020 Jan-Dec |
1 |
| 4 |
33256760 | Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. | 2020 Nov 30 |
1 |
| 5 |
24008638 | [Successful resection of lung cancer with idiopathic pulmonary fibrosis treated by pirfenidone during perioperative period]. | 2013 Sep |
1 |